Skip to content

Pharminent

cropped-ChatGPT-Image-May-28-2026-10_46_23-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Policy / Pricing
  • Minnesota’s 340B Hospitals Make One Billion More From 340B Than They Spend on Uncompensated Care
  • Policy / Pricing

Minnesota’s 340B Hospitals Make One Billion More From 340B Than They Spend on Uncompensated Care

Drug Channels

By Bryce Platt, PharmD Minnesota's new 340B data reveal a growing disconnect between the program's size and the value Minnesotans receive in return.

Policy / PricingRead full story

pharminent April 23, 2026 (Last updated: April 23, 2026)

Drug Channels

By Bryce Platt, PharmD Minnesota’s new 340B data reveal a growing disconnect between the program’s size and the value Minnesotans receive in return.

Policy / PricingRead full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Sanofi receives FDA approval for Tzield in paediatric diabetes
Next: AAN 2026: J&J, Kyverna, Capricor and Praxis showcase practice-changing data

Related Stories

  • Policy / Pricing

The next FDA commissioner must be a champion for gene therapies

pharminent June 5, 2026
  • Policy / Pricing

Stakeholders want Makary’s voucher program paused, call for FDA independence

pharminent June 5, 2026
  • Policy / Pricing

SCOTUS backs generic firm Hikma in skinny label dispute

pharminent June 4, 2026

You May Have Missed

  • Commercial

Lilly and Novo face off at ADA 2026 as others seek to compete in obesity

pharminent June 5, 2026
  • Market Access

Medicare Advantage in 2026: Enrollment Update and Key Trends

pharminent June 5, 2026
  • Policy / Pricing

The next FDA commissioner must be a champion for gene therapies

pharminent June 5, 2026
  • Clinical Data

Otsuka energizes IgA neuropathy space with new Phase 3 Voyxact data

pharminent June 5, 2026
Copyright © 2026 All rights reserved. | ReviewNews by AF themes.